Everything below concerns drug affinity complex. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
=== Physical volume of an organism === This concept is related to multi-compartmentalization. Any drugs within an organism will act as a solute and the organism's tissues will act as solvents. The differing specificities of different tissues will give rise to different concentrations of the drug within each group. Therefore, the chemical characteristics of a drug will determine its distribution within an organism. For example, a liposoluble drug will tend to accumulate in body fat and water-soluble drugs will tend to accumulate in extracellular fluids. The volume of distribution (VD) of a drug is a property that quantifies the extent of its distribution. It can be defined as the theoretical volume that a drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma. It can be determined from the following formula:
known as dissociation in the context of acid–base reactions. The chemical species HA is an acid that dissociates into A−, called the conjugate base of the acid, and a hydrogen ion, H+. The system is said to be in equilibrium when the concentrations of its components do not change over time, because both forward and backward reactions are occurring at the same rate. The dissociation constant is defined by
Williams cites the Mahatanhasankhaya Sutta as showing how dependent origination is to be seen as an alternative theory to such views. According to Williams, dependent origination allows the Buddha to replace a view of the world based on unchanging selves "with an appeal to what he sees as being its essentially dynamic nature, a dynamism of experiences based on the centrality of causal conditioning." Bhikkhu Analayo writes that "dependent arising is the other side of the coin of emptiness, in the sense of the absence of a substantial and unchanging entity anywhere in subjective experience. Experience or existence is nothing but conditions. This leaves no room for positing a self of any type." According to Eisel Mazard, the twelve Nidanas are a description of "a sequence of stages prior to birth", as an "orthodox defense against any doctrine of a 'supernal self' or soul of any kind [...] excluding an un-mentioned life-force (jīva) that followers could presume to be additional to the birth of the body, the arising of consciousness, and the other aspects mentioned in the 12-links formula." According to Mazard, "many later sources have digressed from the basic theme and subject-matter of the original text, knowingly or unknowingly."
The Michel I Government was the Federal Government of Belgium formed following the 2014 Belgian government formation and sworn in on 11 October 2014. The administration was a centre-right coalition of the New Flemish Alliance (N-VA), the Christian Democratic and Flemish (CD&V), the Open Flemish Liberals and Democrats (Open Vld) and the Reformist Movement (MR). The prime minister was Charles Michel. The government had an agenda of socio-economic reforms, especially through austerity measures, with its priorities being improving Belgium's economic competitiveness and reducing unemployment. It fell in December 2018 over the Global Compact for Migration. It was followed by the Michel II Government as a centre minority coalition cabinet of Christian Democratic and Flemish (CD&V), the Open Flemish Liberals and Democrats (Open Vld) and the Reformist Movement (MR). On 26 October 2019, it was announced that Sophie Wilmès would take over the role of prime minister from Michel on 1 November 2019, and form a new government as the first ever female prime minister of Belgium.
=== X-rays === The discovery of X‑rays by Wilhelm Röntgen in 1895 led to widespread experimentation by scientists, physicians, and inventors. Many people began recounting stories of burns, hair loss and worse in technical journals as early as 1896. In February of that year, Professor Daniel and Dr. Dudley of Vanderbilt University performed an experiment involving X-raying Dudley's head that resulted in his hair loss. A report by Dr. H.D. Hawks, of his suffering severe hand and chest burns in an X-ray demonstration, was the first of many other reports in Electrical Review. Other experimenters, including Elihu Thomson and Nikola Tesla, also reported burns. Thomson deliberately exposed a finger to an X-ray tube over a period of time and suffered pain, swelling, and blistering. Other effects, including ultraviolet rays and ozone, were sometimes blamed for the damage, and many physicians still claimed that there were no effects from X-ray exposure at all. Despite this, there were some early systematic hazard investigations, and as early as 1902 William Herbert Rollins wrote almost despairingly that his warnings about the dangers involved in the careless use of X-rays were not being heeded, neither by industry nor by his colleagues. By this time, Rollins had proved that X-rays could kill experimental animals, could cause a pregnant guinea pig to abort, and that they could kill a foetus. He also stressed that "animals vary in susceptibility to the external action of X-light" and warned that these differences be considered when patients were treated by means of X-rays.
Sources: en.wikipedia.org
== Structure == The posterior pituitary consists mainly of neuronal projections (axons) of magnocellular neurosecretory cells extending from the supraoptic and paraventricular nuclei of the hypothalamus. These axons store and release neurohypophysial hormones oxytocin and vasopressin into the neurohypophyseal capillaries, from there they get into the systemic circulation (and partly back into the hypophyseal portal system). In addition to axons, the posterior pituitary also contains pituicytes, specialized glial cells resembling astrocytes assisting in the storage and release of the hormones. Classification of the posterior pituitary varies, but most sources include the two regions below:
Hans Studener (1966–1969) Kurt Holke (1969–1971) Horst Scherbaum (1971–1976) Manfred Pfeifer (1976–1978) Heinz Joerk (1978–1979) Harro Miller (1979–1985) Hans-Ulrich "Uli" Thomale (1985 – February 1990) Gunter Böhme (February 1990 – 27 May 1991) VfB Leipzig
Isoleucine (symbol Ile or I) is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group (which is in the protonated −NH+3 form under biological conditions), an α-carboxylic acid group (which is in the deprotonated −COO− form under biological conditions), and a hydrocarbon side chain with a branch (a central carbon atom bound to three other carbon atoms). It is classified as a non-polar, uncharged (at physiological pH), branched-chain, aliphatic amino acid. It is essential in humans, meaning the body cannot synthesize it. Essential amino acids are necessary in the human diet. In plants isoleucine can be synthesized from threonine and methionine. In plants and bacteria, isoleucine is synthesized from a pyruvate employing leucine biosynthesis enzymes. It is encoded by the codons AUU, AUC, and AUA.
Transfer ribonucleic acid (tRNA), formerly referred to as soluble ribonucleic acid (sRNA), is an adaptor molecule composed of RNA, typically 76 to 90 nucleotides in length (in eukaryotes). In a cell, it provides the physical link between the genetic code in messenger RNA (mRNA) and the amino acid sequence of proteins, carrying the correct sequence of amino acids to be combined by the protein-synthesizing machinery, the ribosome. Each three-nucleotide codon in mRNA is complemented by a three-nucleotide anticodon in tRNA. As such, tRNAs are a necessary component of translation, the biological synthesis of new proteins in accordance with the genetic code.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.